A recent clinical trial has shown that the drug abiraterone (which is already being used to treat men with advanced prostate cancer), may also be of very great benefit to patients with localized high-risk prostate cancer.
After 6 months of treatment, the study showed that abiraterone (Zytiga) completely eliminated or nearly eliminated the tumour in the prostate in an unprecendentedly high 34% of men in the trial.
Localized high-risk prostate cancer comprises approx. 15% of all prostate cancer and is often not able to be cured by prostatectomy (removal of the prostate) with most patients eventually dying from the disease.
The disappearance of the tumour in the prostate itself (as shown in the current trial) translates into a much better outcome for patients.
All participants in the trial had hormone therapy (in addition to abiraterone) and all underwent prostatectomy after completing the drug treatment.
A further clinical trial will be required to validate the results but, as yet, has not been planned.
Wednesday, May 23, 2012
Tuesday, May 22, 2012
U.S. task force: End routine prostate cancer screening
NEW YORK (Reuters) -
A task force advising the U.S. government on Monday recommended against routine use of the prostate-cancer screening test called PSA, or prostate specific antigen, for lack of a discernible health benefit.
Like a draft proposal last October, the U.S. Preventive Services Task Force gave PSA screening a D, for "don't recommend" in healthy men.
PSA, a blood test, is a poor screening tool because PSA levels can rise for reasons unrelated to cancer, including age and prostate enlargement. Yet an elevated PSA level can trigger a biopsy to check for cancer.
Most biopsies show no cancer, which means the PSA was a false positive.
Against the tiny benefit of PSA testing, the task force weighed its harms. At least 15 percent of PSA tests will trigger a biopsy, after which up to one-third of men experience pain, fever, bleeding, infection, difficulty urinating, or other problems requiring medical attention, studies show.
"When you stack up those harms, the tiny or zero benefits do not outweigh the risk," said task force co-chair Dr. Michael LeFevre of the University of Missouri Medical School. Because PSA tests cannot distinguish between aggressive and indolent cancer, said ACS's Brawley, "men are rendered impotent and put in diapers, and for what?" he asked. "They never really had cancer in the first place."
Read the full Reuters report:
U.S. task force: End routine prostate cancer screening:
A task force advising the U.S. government on Monday recommended against routine use of the prostate-cancer screening test called PSA, or prostate specific antigen, for lack of a discernible health benefit.
Like a draft proposal last October, the U.S. Preventive Services Task Force gave PSA screening a D, for "don't recommend" in healthy men.
PSA, a blood test, is a poor screening tool because PSA levels can rise for reasons unrelated to cancer, including age and prostate enlargement. Yet an elevated PSA level can trigger a biopsy to check for cancer.
Most biopsies show no cancer, which means the PSA was a false positive.
Against the tiny benefit of PSA testing, the task force weighed its harms. At least 15 percent of PSA tests will trigger a biopsy, after which up to one-third of men experience pain, fever, bleeding, infection, difficulty urinating, or other problems requiring medical attention, studies show.
"When you stack up those harms, the tiny or zero benefits do not outweigh the risk," said task force co-chair Dr. Michael LeFevre of the University of Missouri Medical School. Because PSA tests cannot distinguish between aggressive and indolent cancer, said ACS's Brawley, "men are rendered impotent and put in diapers, and for what?" he asked. "They never really had cancer in the first place."
Read the full Reuters report:
U.S. task force: End routine prostate cancer screening:
Labels:
Prostate,
Prostate Cancer,
Prostate Screening,
PSA
Saturday, May 5, 2012
Video - HIFU for Localized Prostate Cancer
The following video presents Dr. Gerald Chodak discussing the results of a recent study of High Intensity Focussed Ultrasound as used to treat localized prostate cancer.
Saturday, April 28, 2012
FDA approves Vivus's fast-acting Viagra rival
NEW YORK (Reuters) -
Men with erectile dysfunction may not have to plan for sex as far in advance anymore after Vivus Inc won U.S. approval for avanafil, its faster acting rival to Viagra.
Avanafil, which will be sold under the brand name Stendra, is the first new drug in the category in a decade.
While it is recommended that patients take the new pill 30 minutes prior to sexual activity, in clinical trials it has been shown to work in as fast as 15 minutes. Viagra typically takes about an hour to start working.
The most common side effects reported in clinical studies included headache, flushing of the face and other areas, nasal congestion, common cold-like symptoms and back pain.
Read the full Reuters Health report:
FDA approves Vivus's fast-acting Viagra rival
Men with erectile dysfunction may not have to plan for sex as far in advance anymore after Vivus Inc won U.S. approval for avanafil, its faster acting rival to Viagra.
Avanafil, which will be sold under the brand name Stendra, is the first new drug in the category in a decade.
While it is recommended that patients take the new pill 30 minutes prior to sexual activity, in clinical trials it has been shown to work in as fast as 15 minutes. Viagra typically takes about an hour to start working.
The most common side effects reported in clinical studies included headache, flushing of the face and other areas, nasal congestion, common cold-like symptoms and back pain.
Read the full Reuters Health report:
FDA approves Vivus's fast-acting Viagra rival
Wednesday, April 18, 2012
Pricier therapy no better for early prostate cancer
NEW YORK (Reuters Health) -
A new study suggests that expensive, high-tech proton beam radiation doesn't do any more for men with prostate cancer than the most commonly-used option.
Proton beam radiation, heavily promoted by facilities that perform the treatment, also came with a higher risk of certain side effects compared to intensity-modulated radiation therapy (IMRT), researchers found.
The findings suggest that men have multiple radiation options when it comes to treating early, localized prostate cancer.
Though not covered in the new study, their options also include surgery -- or getting no treatment at all and waiting to see how the disease progresses, researchers said.
Read the full Reuters Health report:
Pricier therapy no better for early prostate cancer
A new study suggests that expensive, high-tech proton beam radiation doesn't do any more for men with prostate cancer than the most commonly-used option.
Proton beam radiation, heavily promoted by facilities that perform the treatment, also came with a higher risk of certain side effects compared to intensity-modulated radiation therapy (IMRT), researchers found.
The findings suggest that men have multiple radiation options when it comes to treating early, localized prostate cancer.
Though not covered in the new study, their options also include surgery -- or getting no treatment at all and waiting to see how the disease progresses, researchers said.
Read the full Reuters Health report:
Pricier therapy no better for early prostate cancer
Saturday, April 14, 2012
Prostate & Baldness drugs may have sexual side effects
The changes involve Propecia and Proscar, both of which contain the active ingredient finasteride
The new Propecia label will include "libido disorders, ejaculation disorders, and orgasm disorders that continued after discontinuation of the drug," the FDA said. Propecia is a drug to treat male baldness.
Proscar, which treats symptoms of enlarged prostate, will now have a label that adds "decreased libido that continued after discontinuation of the drug."
In addition, both labels are being revised to "include a description of reports of male infertility and/or poor semen quality that normalized or improved after drug discontinuation," the FDA said.
Read the full story here:
US warns two drugs may have sexual side effects
Tuesday, April 10, 2012
Researchers Find Genes Linked to Aggressive Prostate Cancer
MONDAY, April 9 (HealthDay News)
The discovery of two inherited genetic variations may help doctors identify men at greater risk for aggressive prostate cancer, a new study suggests.
A man's risk for the disease could triple or even quadruple depending on the genetic variant they have, according to the researchers from Weill Cornell Medical College in New York City and elsewhere.
Having a family history of prostate cancer is the strongest risk factor for the disease. As a result, the researchers set out to find DNA that is deleted or duplicated in the genetic information of men with prostate cancer compared to those who do not have the disease.
In testing the effect of the two inherited variants in a lab, the investigators showed that the variants helped cancer cells grow and invade, putting some men at four times greater risk for prostate cancer.
Read the full HealthDay News report here:
Researchers Find Genes Linked to Aggressive Prostate Cancer:
The discovery of two inherited genetic variations may help doctors identify men at greater risk for aggressive prostate cancer, a new study suggests.
A man's risk for the disease could triple or even quadruple depending on the genetic variant they have, according to the researchers from Weill Cornell Medical College in New York City and elsewhere.
Having a family history of prostate cancer is the strongest risk factor for the disease. As a result, the researchers set out to find DNA that is deleted or duplicated in the genetic information of men with prostate cancer compared to those who do not have the disease.
In testing the effect of the two inherited variants in a lab, the investigators showed that the variants helped cancer cells grow and invade, putting some men at four times greater risk for prostate cancer.
Read the full HealthDay News report here:
Researchers Find Genes Linked to Aggressive Prostate Cancer:
Subscribe to:
Posts (Atom)